Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.
| Website: | www.nektar.com |
| Email: | Investors@nektar.com |
| Main Phone: | +1 415 482-5300 |
| Address: | 455 Mission Bay Boulevard South |
| State: | CA |
| City / Town: | San Francisco |
| Country: | USA |
| Postal Code: | 94158 |
| Exchange: | NGS |
| CEO: | Howard W. Robin |
| Employees: | 723 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Examining 5 stocks that could be propelled by 2nd half milestones.
The company is coming off a strong 2017.
Nektar Therapeutics (NKTR) reported positive top-line data for its drug treatment under development in the opioid sector.
Last week, AstraZeneca PLC (AZN) announced top-line results from two Phase 3 trials and one safety extension trial for naloxegol, an oral drug in development for patients with opioid-induced
US-based Nektar Therapeutics (NKTR) released their second quarter earnings report on Aug 8, showing the company narrowly beat earnings loss expectations. As a result, the stock shot up over 12
So, the Fed is going to continue to do what it thinks grows the economy. Why does that surprise, or upset the Street?What’s so bad about what Fed chief Bernanke said yesterday? If the
Initial Jobless Claims fell to 365,000 still above the 350,000 recessionary threshold. Nonmanufacturing ISM fell to 53.5 in April. The Dow Jones Industrial Average traded up to 13284.09 then
Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.
| Website: | www.nektar.com |
| Email: | Investors@nektar.com |
| Main Phone: | +1 415 482-5300 |
| Address: | 455 Mission Bay Boulevard South |
| State: | CA |
| City / Town: | San Francisco |
| Country: | USA |
| Postal Code: | 94158 |
| Exchange: | NGS |
| CEO: | Howard W. Robin |
| Employees: | 723 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Examining 5 stocks that could be propelled by 2nd half milestones.
The company is coming off a strong 2017.
Nektar Therapeutics (NKTR) reported positive top-line data for its drug treatment under development in the opioid sector.
Last week, AstraZeneca PLC (AZN) announced top-line results from two Phase 3 trials and one safety extension trial for naloxegol, an oral drug in development for patients with opioid-induced
US-based Nektar Therapeutics (NKTR) released their second quarter earnings report on Aug 8, showing the company narrowly beat earnings loss expectations. As a result, the stock shot up over 12
So, the Fed is going to continue to do what it thinks grows the economy. Why does that surprise, or upset the Street?What’s so bad about what Fed chief Bernanke said yesterday? If the
Initial Jobless Claims fell to 365,000 still above the 350,000 recessionary threshold. Nonmanufacturing ISM fell to 53.5 in April. The Dow Jones Industrial Average traded up to 13284.09 then
| Last Price 24.03 | Change $ -0.405 | Change % -1.66 | Tick N/A |
| Bid 22.18 | Bid Size 100.00 | Ask 24.45 | Ask Size 7,200.00 |
| Open 24.28 | High 24.53 | Low 23.88 | Prev Close 24.43 |
| Last Trade | Volume 522,976 | 52 Wk Hi 33.80 | 52 Wk Low 13.64 |
| Market Cap 4.3 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 177,989,857.00 | EPS (TTM) -2.62 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 54 | 154 |
| Number of Buys | 27 | 78 |
| Number of Sells | 27 | 76 |
| Net Activity | 1280 | 285373 |
| Last 10 Buys | Shares |
|---|---|
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| R. Scott Greer | 1,000 |
| Dennis L. Winger | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| R. Scott Greer | 1,000 |
| Robert B. Chess | 1,000 |
| R. Scott Greer | 1,000 |
| John Nicholson | 1,000 |
| Jillian B. Thomsen | 1,000 |
| Howard W. Robin | 1,000 |
| Stephen K. Doberstein | 1,000 |
| Maninder Hora | 1,000 |
| Gil M. Labrucherie | 1,000 |
| Robert B. Chess | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 125 | 125 | 125 | 125 |
| Low Target Price Estimate | 63 | 63 | 63 | 54 |
| Mean Target Price Estimate | 98.22 | 102.67 | 102.67 | 93.44 |
| Standard Deviation | 19.08 | 19.72 | 19.72 | 24.14 |
| Date of Most Recent Estimate | 06/04/18 | 05/16/18 | 05/16/18 | 06/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 14 | 2018-06-04 |
| CT ORDER | 1 | 2018-05-22 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 8 | 9 | 8 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.4 | 1.2 | 1.22 | 1.29 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait